Drug Interactions between thiabendazole and Trental
This report displays the potential drug interactions for the following 2 drugs:
- thiabendazole
- Trental (pentoxifylline)
Interactions between your drugs
thiabendazole pentoxifylline
Applies to: thiabendazole and Trental (pentoxifylline)
MONITOR: Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of pentoxifylline and its active hydroxy metabolite (M1), both of which are substrates of the isoenzyme. In a study consisting of eight healthy, nonsmoking volunteers, mean pentoxifylline systemic exposure (AUC) increased by approximately 35% when pentoxifylline 300 mg was administered intravenously one hour after a single 750 mg oral dose of ciprofloxacin, a moderate CYP450 1A2 inhibitor. The R- and S-enantiomers of the M1 metabolite also increased by 39% and 37%, respectively.
MANAGEMENT: Pharmacologic response to pentoxifylline should be monitored more closely whenever a potent or moderate CYP450 1A2 inhibitor is added to or withdrawn from therapy, and the pentoxifylline dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience serious adverse effects such as bleeding, angina, or arrhythmias.
References
- (2001) "Product Information. Trental (pentoxifylline)." Hoechst Marion Roussel
- Magnusson M, Bergstrand IC, Bjorkman S, Heijl A, Roth B, Hoglund P (2006) "A placebo-controlled study of retinal blood flow changes by pentoxifylline and metabolites in humans." Br J Clin Pharmacol, 61, p. 138-47
Drug and food interactions
thiabendazole food
Applies to: thiabendazole
MONITOR: Coadministration with thiabendazole may increase the plasma concentrations of caffeine. The mechanism is thiabendazole inhibition of the CYP450 1A2 metabolism of caffeine. In ten healthy, nonsmoking volunteers, administration of a single 136.5 mg dose of caffeine in combination with a single 500 mg dose of thiabendazole resulted in a nearly 60% increase in the area under the plasma concentration-time curve (AUC) of caffeine compared to administration without thiabendazole. In addition, the half-life of caffeine was increased from 11.9 to 28.6 hours, and oral clearance was reduced by 67% during coadministration with thiabendazole. The formation of paraxanthine from caffeine, which is primarily mediated by CYP450 1A2, was almost completely abolished until after the thiabendazole was cleared from the system.
MANAGEMENT: Patients should be advised that pharmacologic effects of caffeine may be increased during coadministration with thiabendazole.
References
- Bapiro TE, Sayi J, Hasler JA, et al. (2005) "Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans." Eur J Clin Pharmacol, 61, p. 755-61
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.